You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】港交所企穩300元 輪證獲利平倉湧現 恆指牛59749 熊53078/ 港交購13987 牛59247 熊59799
阿思達克 06-22 10:40
投資者繼續憂慮美國疫情有反彈風險,道指上周五先升後回,收報25871點,跌208點(或0.8%)。不過全星期仍累升約1%。恆指上周五收報24643點,升178點(或0.7%),盤中一度高見24776點。港版國安法細節曝光,恆指今早整固,低位曾跌穿24500點,其後重返24600點附近。恆指好倉(牛證及認購權證)上周五淨流出近5300萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流入逾9400萬元,反映投資者續看淡後市。上周五恆指牛證街貨重貨區為收回價23300至23399點,而熊證街貨重貨區為收回價25500至25599點。

資金續炒作受惠中概股回歸的港交所(00388),股份上周五破位高見300.8元,收報300.4元,漲1.4%,為一八年一月以來首次站穩300元之上收市,而港交所曾在一五年高見311.4元的歷史高位。股份今早繼續破頂,突破301元,下方留意10天線(294.4元)的支持力度。上周五有2.87億元北水淨買入港交所。輪證資金流方面,超過1500萬元在上周五淨流出其好倉,淡倉同日則有229萬元淨流入。

阿里巴巴(09988)宣布,「2020年天貓618」的累計下單金額破紀錄達到6982億元人民幣。股份上周五反覆靠穩,收報219元,盤中受制於220元關阻力。今早回落約2%,於215元以下整固,短期支持留意10天線(214元)。上周五分別有955萬和43萬元淨流出其好倉和淡倉。

中國生物製藥(01177)上周五創新高,高見14.96元,收報14.82元,升1.5%。股份今月強勢向上,月內累漲21.9%。今早隨市稍作整固,下試14.7元以下。上周五分別有97萬和3萬元淨流出其好倉和淡倉。

同樣近期呈強的美團點評(03690),上周五於170元以上爭持,高位曾再逼近歷史高位175.9元,收市微升0.8%報174元,連升第四日。美團宣布,將在政府部門指導下組織全部在京外賣騎手進行核酸檢測,股份今早略回,曾跌穿172元。上周五有671萬元淨流出其好倉,淡倉同日則有402萬元淨流入。

瑞通相關認股證之選擇:

恆指輕微價外、中短期購25622,行使價:25920點,2020年10月到期,實際槓桿:10.8倍

恆指輕微價外、長期沽12644,行使價:22800點,2021年3月到期,實際槓桿:5.1倍

港交輕微價外、中年期購13987,行使價:338.88元,2021年1月到期,實際槓桿:7.2倍

港交價外、中年期沽12352,行使價:248.8元,2021年1月到期,實際槓桿:6.7倍

中藥輕微價外、長期購14335,行使價:15.68元,2021年6月到期,實際槓桿:2.8倍

美團價外、中短期購14356,行使價:201.08元,2020年12月到期,實際槓桿:5.2倍

美團價外、中短期沽13137,行使價:138元,2020年12月到期,實際槓桿:4.1倍

阿里輕微價外、短期購22402,行使價:232.8元,2020年8月到期,實際槓桿:11.4倍

阿里輕微價外、中短期沽22404,行使價:198.88元,2020年10月到期,實際槓桿:6.3倍

瑞通相關牛熊證之選擇:

恆指牛證59749,收回價:23910點,槓桿比率:35.6倍

恆指熊證53078,收回價:24980點,槓桿比率:35.6倍

港交牛證59247,收回價:274.8元,槓桿比率:10倍

港交熊證59799,收回價:312.88元,槓桿比率:20.2倍

中藥牛證61534,收回價:9.9元,槓桿比率:2.7倍

美團牛證51702,收回價:166.899元,槓桿比率:22.4倍

美團熊證59233,收回價:179.9元,槓桿比率:13倍

阿里牛證54040,收回價:208.89元,槓桿比率:21.1倍

阿里熊證60927,收回價:232.888元,槓桿比率:10.1倍

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account